Source: International Congress 2017 – Management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Naya (Uxbridge, United Kingdom). Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study. 3248

Member's Comments

No comment yet.

Related content which might interest you: Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes Source: International Congress 2017 – COPD management Year: 2017 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Preventing clinically important deterioration with single-inhaler triple therapy in COPD Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018 Year: 2018 Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Investigating the percentage of patients with COPD who could benefit from a change in inhaler Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002 Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations? Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Symptomatic burden of COPD for patients receiving dual or triple therapy Source: International Congress 2017 – Management of COPD Year: 2017 Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 A realistic study assessing inhaled treatment compliance in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019